RE:RE:This comment from LTF ay be of interest re: NGMThe author of that info, as well as just about everyone else, believes there will be plenty of room for more than a few players in the NASH space and that many of the drugs will be prescribed in combination therapy because of their different MOA's. So, even if TH is a bit late to the NASH party, it should still be in time to get a nice piece of cake. And NGM's failure really helps TH as most thought they would be eating that cake well ahead of TH. So, the party is looking to have fewer people at it than ever. The fewer, the better for all who get dressed up and make it to the party.
PWIB123 wrote: Assuming MDGL is first to market and "has the sizeable lucrative NASH therapeutics market on approval", where does that leave the opportunity for THTX?